XORTX Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
XRTX New York 8731 https://www.xortx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for XORTX Therapeutics Inc

XORTX Announces PKD Presentation - Jun 6th, 2023 11:00 am
XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency - May 24th, 2023 11:00 am
FDA Confirms Eligibility of XORLO™ for Accelerated Approval - May 4th, 2023 11:00 am
XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Kidney Disease - Apr 21st, 2023 11:00 am
XORTX Announces Type D Meeting with FDA to be held May 1, 2023 - Mar 14th, 2023 11:00 am
XORTX Provides Update on 2022 Achievements and 2023 Planned Milestones - Feb 7th, 2023 12:00 pm
XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease - Feb 1st, 2023 12:00 pm
XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial - Jan 19th, 2023 12:00 pm
XORTX Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression - Jan 3rd, 2023 12:00 pm
XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Study - Dec 19th, 2022 12:00 pm
XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Dec 8th, 2022 12:00 pm
XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study - Nov 28th, 2022 12:00 pm
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - Nov 25th, 2022 10:45 pm
XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer - Nov 16th, 2022 12:00 pm
Sidoti's November Micro-Cap Virtual Conference - Nov 8th, 2022 8:40 pm
XORTX Presents New Proof of Concept Data at American Society of Nephrology - Nov 3rd, 2022 9:00 pm
XORTX Announces Participation at Upcoming Investor Conferences - Nov 3rd, 2022 2:15 pm
XORTX Receives Further No Objection Letter from Health Canada - Oct 26th, 2022 11:00 am
XORTX Sponsored American Society of Nephrology Study Abstract Available Online - Oct 25th, 2022 11:00 am
XORTX Announces Closing of US$5 Million Public Offering - Oct 7th, 2022 10:02 pm